Looking at the quarterly and accelerating cashburn with trials, it seems to me they've got a window of about 12 months within which they'll have to cut a partnership/licensing deal with a pharma or else tap the market for more money. That is, of course, unless they get taken out first.
Add to My Watchlist
What is My Watchlist?